65
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients

, , , , , , & show all
Pages 2129-2136 | Published online: 01 Jul 2016

References

  • Di PardoBJBronsonNWDiggsBSThomasCRJrHunterJGDolanJPThe global burden of esophageal cancer: A disability-adjusted life-year approachWorld J Surg201640239540126630937
  • NakamuraKKatoKIgakiHThree-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study)Jpn J Clin Oncol201343775275523625063
  • SmitJKMuijsCTBurgerhofJGSurvival after definitive (chemo) radiotherapy in esophageal cancer patients: A population-based study in the north-East NetherlandsAnn Surg Oncol20132061985199223274534
  • CooperJSGuoMDHerskovicAChemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology GroupJAMA1999281171623162710235156
  • HanJZhuWYuCZhouXLiTZhangXClinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasisTumori2012981606522495703
  • van HagenPHulshofMCvan LanschotJJPreoperative chemoradiotherapy for esophageal or junctional cancerN Engl J Med2012366222074208422646630
  • StahlMMarietteCHaustermansKCervantesAArnoldDESMO Guidelines Working GroupOesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 65156
  • StahlMBudachWMeyerHJCervantesAESMO Guidelines Working GroupEsophageal cancer: Clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 54649
  • RuhstallerTWidmerLSchullerJCMulticenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02)Ann Oncol20092091522152819465425
  • HuangTCHsuCHLinCCTuYKSystematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancerJpn J Clin Oncol201545111023102826246479
  • ZemanovaMPetruzelkaLPazdroAProspective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-upDis Esophagus201023216016719515190
  • EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
  • LiuSYangHZhangPNeoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case–control studyRadiother Oncol2015116226226826243678
  • HoningJSmitJKMuijsCTA comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patientsAnn Oncol201425363864324492674
  • LiQQLiuMZHuYHLiuHHeZYLinHXDefinitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinomaDis Esophagus201023325325919732130
  • WeinsteinCJordanKGreenSASingle-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trialAnn Oncol201627117217826449391
  • AbeMHirashimaYKasamatsuYEfficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trialSupport Care Cancer201624267568226130365
  • ScheerRVFakirisAJJohnstonePAQuantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancerInt J Radiat Oncol Biol Phys2011804996100120584580
  • ChangWLWangWLChuangTJResponse evaluation with endoscopic ultrasound and computed tomography in esophageal squamous cell carcinoma treated by definitive chemoradiotherapyJ Gastroenterol Hepatol201530346346925088453
  • SjoquistKMBurmeisterBHSmithersBMSurvival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysisLancet Oncol201112768169221684205
  • Courrech StaalEFAlemanBMvan VelthuysenMLChemoradiation for esophageal cancer-Institutional experience with three different regimensAm J Clin Oncol201134434334920562589
  • NomuraMOzeIAbeTImpact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysisCancer Chemother Pharmacol201576235736326092324
  • YangHYaoJWenHClinical evaluations of neoadjuvant chemotherapy with DN and FP regimen for patients with middle or lower thoracic locally advanced esophageal squamous cell carcinomaZhonghua Yi Xue Za Zhi201595191530153326178509
  • FuCLiBGuoLPhase II study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed and cisplatin for locally advanced oesophageal squamous cell carcinomaBr J Radiol20148710372013065624666012
  • RizviFHSyedAAKhattakSRizviSSKazmiSAKhanMQComplete pathological response after neoadjuvant treatment in locally advanced esophageal cancer predicts long term survival: a retrospective cohort studyInt J Surg201412662162524802520
  • KordesSvan Berge HenegouwenMIHulshofMCPreoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT studyInt J Radiat Oncol Biol Phys201490119019625195993
  • HechtJRBangYJQinSKLapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2- positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC – A randomized Phase III trialJ Clin Oncol201634544345126628478